Background: Breast cancer micrometastases are frequently found during pathological examination of sentinel lymph nodes and complete axillary lymph node dissection. Despite this, their clinical relevance is still debated. The aim of this study is to investigate features that affect disease-free survival (DFS) and overall survival (OS) in patients with nodal micrometastases from breast cancer.
introduction Small (£2 mm) neoplastic deposits are frequently disclosed during the examination of sentinel lymph nodes (SLNs) and, less frequently, of complete axillary lymph node dissection (ALND). They should be regarded as different from true metastases according to the latest American Joint Committee on Cancer (AJCC) staging system [1] and classified according to their size as 'micrometastases' ('mic', tumor deposit 0.2-2 mm) or 'isolated tumor cells' (ITC, tumor deposit <0.2 mm). While the role of true metastases (>2 mm) is well recognized and both surgical and medical treatments of these patients are standardized, the impact of micrometastases on outcome and therapeutic strategy is still under debate.
The first few studies on this topic did not disclose any survival difference as compared with node-negative cases, and hence indicating that these patients should be treated as node negative [2] [3] [4] [5] . More recently, however, studies with more patients and longer follow-up showed a worse outcome, overlapping or at least achieving that of node-positive patients and hence prompting a medical treatment [6] [7] [8] [9] . There are increasing data showing that pathological features of nodal micrometastasis (i.e. size and site) can probably explain this behavior. Viale et al. [10] firstly observed that micrometastasis >1 mm can be a predictor of additional nodal involvement in SLN-positive patients. The same also applies to parenchymal localization [11, 12] . By contrast, Colleoni et al. [13] failed to demonstrate an impact of size of micrometastasis on clinical outcome. Finally, data on clinical impact of site of micrometastasis (sinusal versus parenchymal) are lacking.
In this work we aimed to verify if patients affected by breast cancer with nodal micrometastasis behave worse as compared with node-negative patients and, in this case, if pathological features of nodal micrometastasis (i.e. size or site) correlate with clinical outcomes in patients affected by breast cancer. To address this issue we conducted a retrospective analysis of a series of earlystage breast cancer patients harboring a nodal micrometastasis followed up for a median 5-year period in a single institution. [16] , (ix) size (£1 mm versus >1 mm) and (x) site (sinus or parenchyma) of the micrometastasis within the lymph node. SLNs were examined with serial sections carried out either on frozen or on paraffinembedded tissues as previously reported [17] . For ALND, in order to exclude the possibility of true metastatic disease, we recut all paraffin blocks and examined three additional hematoxylin and eosin-stained sections obtained at each 100 lm level.
treatment and follow-up
All patients with breast-conserving surgery underwent radiation therapy. In addition, on the basis of the primary tumor characteristics, hormonal receptor status, HER-2 status and/or age, patients were candidates for systemic adjuvant therapy according to departmental treatment policy. The treatment choice was the result of an interdisciplinary discussion among oncologists, surgeons, radiotherapists and pathologists that took into account the St Gallen Consensus Guidelines [18] [19] [20] . An anthracycline-containing regimen (i.e. doxorubicin and cyclophosphamide for six courses) was regarded as the first option in patients with intermediate/high-risk disease [21] . In case of comorbidities or patients' preference, i.v. cyclophosphamide, methotrexate and fluorouracil for a duration of six courses was considered [22] . For patients with endocrine-responsive disease, adjuvant endocrine therapy according to menopausal status was indicated. Premenopausal patients were treated with tamoxifen 20 mg/day for 5 years plus gonadotropin-releasing hormonal analogs for at least 3 years. Postmenopausal women were treated with tamoxifen for 5 years until 2005 and after this date, they were treated with tamoxifen 20 mg/day for 2 years followed by an aromatase inhibitor (anastrozole 1 mg/day) for 3 years according to American Society of Clinical Oncology Technology Assessment Panel recommendations [23] and based on the results of the Arimidex, Tamoxifen, Alone or in Combination study [24] . Furthermore, from August 2006, based on the results of the herceptin adjuvant study [25] , HER-2-positive breast cancers were treated with trastuzumab every 21 days for 1 year.
All patients had follow-up examinations at least every 6 months for the first 5 years and at 12-month intervals thereafter, unless otherwise indicated according to risk factors. The patients' routine evaluation included clinical examination with laboratory assessment at each visit, as well as yearly chest X-ray, abdominal ultrasound, mammography and breast ultrasound.
Disease-free survival (DFS) was defined as time from day of surgery (study entry) until time of disease recurrence or death from any cause. Patients who had no evidence of recurrent disease were censored at the date of the last follow-up. Overall survival (OS) was calculated as the time from study entry until death from any cause; patients who were alive on the date of last follow-up were excluded on that date.
statistical analysis
Survival analysis was carried out by plotting survival curves according to the Kaplan-Meier method [26] . The study population was stratified according to principle breast features and groups were compared by means of the log-rank test. Clinical-pathological features that were statistically significant on univariate analysis were tested using multivariate Cox proportional hazards regression models, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated [27] . A P value <0.05 was considered to be the limit of statistical significance. All statistical analyses were carried out using the R-package.
results
Among the originally selected 144 patients, 12 with ITC were excluded. The remaining 132 patients had nodal micrometastasis detected in complete axillary dissection (ALND group) in 56 cases or in SLN followed by ALND (SLN + ALND group) in 76 cases. Within the latter group, 10 patients had ALND positive for additional metastases and were considered separately [11] . The remaining 122 patients were considered for the outcome analysis.
Medical treatments were administered as follows. Seventytwo patients (60.5%) received adjuvant chemotherapy consisting of anthracycline-containing regimens in 60 cases; endocrine therapy was indicated in 93.8% patients. Sixty-two patients (52.1%) received tamoxifen for 5 years; 23 patients (24.4%) received tamoxifen plus luteinizing-hormone releasing hormone-analogous and 21 patients (17.6%) had tamoxifen for 2 years followed by anastrozole for 3 years. Trastuzumab was administered to five patients. One-hundred patients (82.0%) also received radiotherapy.
At the time of last follow-up, 22 of 122 (18.0%) patients had developed local and/or distant recurrence: 4 local relapses; 3 local and distant recurrences; 15 distant relapses. Of the 122 patients, 8 died of the disease (6.6%). The median follow-up was 60 months (12-189 months). Five-year DFS and OS were, respectively, 82.6% and 92.6%. The median time to recurrence was 38 months (1-148 months).
Clinical and pathological features impacting on DFS and OS, on univariate analysis, are illustrated in Table 1 . Briefly, pathological features of the primary tumor related to poorer DFS were multifocality (P = 0.002), tumor size >2 cm (P = 0.022), grade (P = 0.022), absence of ER (P < 0.001) and PR (P < 0.001), HER-2 overexpression (P = 0.006), vascular invasion (P = 0.039) and proliferative fraction ‡20% (P = 0.034). Micrometastasis localization (sinusal versus. parenchymal) was associated with poorer DFS (P = 0.010; Table  1 and Figure 1 ). Sinusal metastases were significantly smaller than those localized within the nodal parenchyma (odds ratio = 3.4, 95% CI 1.5-7.7] but neither the size nor the site of the micrometastases was statistically related to the clinicalpathological features of the primary tumor. Poorer OS was significantly correlated with multifocality (P < 0.001) and absence of receptors (P = 0.005).
In the multivariate analysis, we considered only variables that were significant in the univariate model according to their clinical relevance [i.e. type of nodal dissection (SLN + ALND Table 2 . A higher hazard risk was observed for negative receptor status (HR = 11.2, 95% CI 4.1-31.1) and micrometastasis localized within the node sinus (HR = 3.7, 95% CI 1.2-11.4). Only receptor status confirmed a significant impact on OS (HR = 8.2, 95% CI 1.8-37.0).
discussion
In the present series we retrospectively evaluated the outcome of a cohort of 122 patients affected by breast cancer with nodal micrometastasis. A great number of these patients died of disease (8 of 122, 6.6%) or developed distant metastases (18 of 122, 14.8%), a remarkable aspect since they had minimal nodal involvement and were, mostly, treated with adjuvant anthracycline-based chemotherapy. As compared with a series of patients affected by pT1N0 collected and treated at the same institution [28] , we observed similar values for OS (92.6% versus 96%) but strikingly different DFS rates (82.6% versus 94%). This supports the hypothesis that patients with micrometastases from breast cancer behave worse as compared with node-negative patients and this is in keeping with the results of larger series, mostly coming from database analysis [9] . In our series, multifocality, grade, absence of ER and PR, HER-2 overexpression, vascular invasion and proliferative fraction ‡20% were negatively related to the prognosis. A statistically significant difference was also observed for DFS comparing the ALND and SLN/ALND groups, the most probable explanation being that patients undergoing ALND by default had a larger tumor or multifocality. All these data confirm a main role for the primary tumor on the prognosis of patients with minimal nodal involvement. In particular, a negative receptor status seems the most powerful indicator of a worse outcome.
In addition, we also observed that among the whole patients, those with micrometastases localized within the nodal sinus behave worse. Sinusal metastases were significantly smaller than parenchymal ones, but neither the size nor the site of the micrometastases was related to the features of the primary tumor. Thus, it can be speculated that metastatic cancer cells possess ab initio a peculiar fingerprint, influencing their behavior. A possible explanation can be represented by chemokines profile. Breast cancer cells express CXCR4 and CCR7 which bind to CXCL12 and CCL21 [29] . In malignant melanoma, which shares this profile with breast cancer, it has been demonstrated that metastatic cells may evade nodal drainage due to the initial absence of CXCR4 and CCR7 [30] . The hypothesis is that CXCR4/CCR7-negative breast neoplastic cells escape nodal drainage and float free within nodal sinuses. In contrast, CXCR4/CCR7-positive breast neoplastic cells are initially captured by nodal parenchyma and, if the tumor burden increases, may force down the recruitment of immune cells and can give rise to further metastatic spread.
The topic of clinical relevance of nodal micrometastases is one of the most debated in the management of patients with breast cancer. To date, published results are contrasting, both in terms of impact on outcome (present versus absent) and management (medical treatment as node positive versus medical treatment as node negative). This scenario is probably due to several causes including not only true biological behavior but also bias as short follow-up, small series and incomplete clinical-pathological data. More recently, however, there have been studies strongly supporting a relevant role for micrometastases. Most of these studies came from database analysis and did not explain how micrometastasis impact on the outcome. Our results not only confirm this figure but also seem to support the hypothesis that pathological features of micrometastasis mirror their biological attitude. Thus, as firstly observed in the present work, sinusal micrometastasis should be considered a marker of worse outcome while those >1 mm or localized within nodal parenchyma should be considered as markers of additional nodal involvement. Concerning the other aspect, namely medical treatment of these patients, we noticed that the anthracycline-based schedule was insufficient to prevent recurrence. This not only seems to support medical therapy in patients with micrometastasis, as recently concluded by Grabau [9] , but also indicates that medical armamentarium should be implemented, possibly with different biological drugs, in the future.
In conclusion, our results indicate that in patients affected by breast cancer, in addition to the well-known pathological features of the primary tumor, nodal sinus localization of micrometastases significantly correlates with a worse prognosis and may provide additional prognostic information. Larger series are needed to verify these data and indicate how to manage these patients.
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